A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913

BACKGROUND: This phase II study was designed to determine the efficacy of the mammalian target of rapamycin (mTOR) inhibitor everolimus administered daily with conventional radiation therapy and chemotherapy in patients with newly diagnosed glioblastoma. METHODS: Patients were randomized to radiatio...

詳細記述

保存先:
書誌詳細
出版年:Neuro Oncol
主要な著者: Chinnaiyan, Prakash, Won, Minhee, Wen, Patrick Y, Rojiani, Amyn M, Werner-Wasik, Maria, Shih, Helen A, Ashby, Lynn S, Michael Yu, Hsiang-Hsuan, Stieber, Volker W, Malone, Shawn C, Fiveash, John B, Mohile, Nimish A, Ahluwalia, Manmeet S, Wendland, Merideth M, Stella, Philip J, Kee, Andrew Y, Mehta, Minesh P
フォーマット: Artigo
言語:Inglês
出版事項: Oxford University Press 2018
主題:
Clinical Investigations
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5892159/
https://ncbi.nlm.nih.gov/pubmed/29126203
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox209
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料